Induction-related mortality during ATO-based induction
| . | Total deaths . | Hemorrhage . | Differentiation syndrome . | Infection . | Cardiovascular . | Other . |
|---|---|---|---|---|---|---|
| APML432 | ||||||
| ATRA+IDA+ATO (n = 124) | 4 (3.2%) | 2 (1.6%) | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | 1 (0.8%) |
| APL040633 | ||||||
| ATRA+IDA (n = 133) | 4 (3.0%) | 0 (0.0%) | 2 (1.5%) | 1 (0.8%) | 1 (0.8%) | 0 (0.0%) |
| ATRA+ATO (n = 122) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| AML177 | ||||||
| ATRA+IDA (n = 119) | 11 (9.2%) | 3 (2.5%) | 0 (0.0%) | 3 (2.5%) | 0 (0.0%) | 5 (4.5%) |
| ATRA+ATO+/−GO (n = 116) | 6 (5.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 3 (2.6%) | 2 (1.7%) |
| . | Total deaths . | Hemorrhage . | Differentiation syndrome . | Infection . | Cardiovascular . | Other . |
|---|---|---|---|---|---|---|
| APML432 | ||||||
| ATRA+IDA+ATO (n = 124) | 4 (3.2%) | 2 (1.6%) | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | 1 (0.8%) |
| APL040633 | ||||||
| ATRA+IDA (n = 133) | 4 (3.0%) | 0 (0.0%) | 2 (1.5%) | 1 (0.8%) | 1 (0.8%) | 0 (0.0%) |
| ATRA+ATO (n = 122) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| AML177 | ||||||
| ATRA+IDA (n = 119) | 11 (9.2%) | 3 (2.5%) | 0 (0.0%) | 3 (2.5%) | 0 (0.0%) | 5 (4.5%) |
| ATRA+ATO+/−GO (n = 116) | 6 (5.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 3 (2.6%) | 2 (1.7%) |
GO, gemtuzumab ozogamicin.